FBCE yields 2000000.00% · PFE yields 6.13%● Live data
📍 FBCE pulled ahead of the other in Year 1
Combined, FBCE + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FBCE + PFE for your $10,000?
FiberCore, Inc. develops, manufactures, and markets single-mode and multimode optical fiber, and optical fiber preforms for the telecommunications and data communications industry. The company's principal operating units are FiberCore Jena A.G. (FCJ), its wholly owned subsidiary in Germany; and Xtal FiberCore Brasil S.A. (Xtal), the company's 90% owned subsidiary in Campinas, Brazil. FCJ manufactures both multimode and single-mode fiber and preforms with an emphasis on the multimode market; Xtal manufactures both single-mode and multimode fiber, and single-mode preforms with an emphasis on the single-mode market. Through its subsidiary, FiberCore Systems, Inc., the company designs, installs, and maintains optical fiber networks, wide area networks, and non-fiber optic networks primarily in the Northeast U.S., for local area network applications, such as those used in hospitals, universities, government, and commercial buildings. The company markets its optical fiber products under the trademarks, InfoGlas®, EconoGrade®, and ValuGrade®. Fibercore competes with Corning, Inc.; Furukawa/OFS; Alcatel; Draka; Samsung; and Sumitomo. FiberCore, Inc. was founded in 1987 and is based in Charlton, Massachusetts. On October 6, 2004 the voluntary petition of FiberCore, Inc. for reorganization under Chapter 11 was converted to liquidation under Chapter 7. The Company had filed for Chapter 11 on November 14, 2003.
Full FBCE Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.